• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A comparison between vitamin K antagonists and new oral anticoagulants.

作者信息

Jolobe Oscar M P

机构信息

Manchester Medical Society, Manchester, UK.

出版信息

Br J Clin Pharmacol. 2017 Nov;83(11):2589-2590. doi: 10.1111/bcp.13347. Epub 2017 Jul 12.

DOI:10.1111/bcp.13347
PMID:28703392
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5651312/
Abstract
摘要

相似文献

1
A comparison between vitamin K antagonists and new oral anticoagulants.维生素K拮抗剂与新型口服抗凝剂的比较。
Br J Clin Pharmacol. 2017 Nov;83(11):2589-2590. doi: 10.1111/bcp.13347. Epub 2017 Jul 12.
2
[Treatment of bleeding complications due to oral anticoagulant drugs].[口服抗凝药物所致出血并发症的治疗]
Laryngorhinootologie. 2015 Oct;94(10):697-709. doi: 10.1055/s-0034-1564071. Epub 2015 Oct 15.
3
Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.非维生素K口服抗凝药用于非瓣膜性心房颤动的相对疗效和安全性：在三个患者亚组中比较阿哌沙班、达比加群、利伐沙班和依度沙班的网状Meta分析
Int J Cardiol. 2016 Feb 1;204:88-94. doi: 10.1016/j.ijcard.2015.11.084. Epub 2015 Nov 17.
4
Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.华法林与四种非维生素K拮抗剂口服抗凝剂用于卒中二级预防时的复发卒中量及预后分析
J Stroke Cerebrovasc Dis. 2018 Feb;27(2):338-345. doi: 10.1016/j.jstrokecerebrovasdis.2017.09.007. Epub 2017 Oct 13.
5
New Oral Anticoagulants: What Prescribers Should Know; Differences and Similarities between Warfarin and "New Agents" (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) - Review of Indications, Contraindications and Safety of Use.新型口服抗凝药：处方医生应了解的内容；华法林与“新型药物”（达比加群、利伐沙班、阿哌沙班、依度沙班）之间的异同——适应证、禁忌证及使用安全性综述
S D Med. 2016 Aug;69(8):363-369.
6
Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.墨西哥心房颤动患者卒中预防的挑战与治疗：综述
Am J Cardiovasc Drugs. 2016 Jun;16(3):171-82. doi: 10.1007/s40256-016-0163-6.
7
Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study.非维生素 K 拮抗剂口服抗凝剂和华法林在房颤患者中与缺血性和出血性卒中的相关性：一项全国性队列研究。
Eur Heart J. 2017 Mar 21;38(12):907-915. doi: 10.1093/eurheartj/ehw496.
8
Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases.当前临床医生对非维生素 K 拮抗剂口服抗凝剂在挑战性临床病例中的应用的看法。
Turk Kardiyol Dern Ars. 2020 Apr;48(3):289-303. doi: 10.5543/tkda.2020.16359.
9
Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials.新型口服抗凝剂对房颤患者胃肠道出血的影响：一项干预性试验的荟萃分析。
Dig Liver Dis. 2015 May;47(5):429-31. doi: 10.1016/j.dld.2015.01.159. Epub 2015 Feb 7.
10
Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies.非维生素 K 拮抗剂口服抗凝剂在房颤患者二级卒中预防中的作用：一项增加观察性研究的更新分析。
Cardiovasc Drugs Ther. 2020 Aug;34(4):569-578. doi: 10.1007/s10557-020-06961-7.

本文引用的文献

1
Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study.房颤患者使用维生素K拮抗剂、非维生素K拮抗剂口服抗凝药和阿司匹林相关的大出血和中风风险：一项队列研究
Br J Clin Pharmacol. 2017 Aug;83(8):1844-1859. doi: 10.1111/bcp.13265. Epub 2017 Mar 24.
2
Emergency LP in a patient receiving dabigatran after antagonization with idarucizumab.在使用艾达赛珠单抗拮抗后接受达比加群治疗的患者中进行紧急腰椎穿刺。
Am J Emerg Med. 2017 Apr;35(4):662.e3-662.e4. doi: 10.1016/j.ajem.2016.10.068. Epub 2016 Oct 29.
3
Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention.降低接受直接口服抗凝剂预防卒中患者的出血风险。
Int J Gen Med. 2016 Oct 11;9:337-347. doi: 10.2147/IJGM.S109104. eCollection 2016.
4
Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience.直接口服抗凝剂与华法林所致出血：临床经验
Am J Med. 2016 Nov;129(11S):S33-S40. doi: 10.1016/j.amjmed.2016.06.003. Epub 2016 Aug 30.
5
The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands.《2016年IUPHAR/BPS药理学指南：迈向1300个蛋白质靶点与6000种配体之间的精准定量相互作用》
Nucleic Acids Res. 2016 Jan 4;44(D1):D1054-68. doi: 10.1093/nar/gkv1037. Epub 2015 Oct 12.
6
Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis.华法林治疗的心房颤动患者中风或全身性栓塞的风险：系统评价和荟萃分析。
Stroke. 2013 May;44(5):1329-36. doi: 10.1161/STROKEAHA.113.000883. Epub 2013 Mar 12.
7
Frequency and risk factors for spontaneous hemorrhagic transformation of cerebral infarction.
J Stroke Cerebrovasc Dis. 2004 Nov-Dec;13(6):235-46. doi: 10.1016/j.jstrokecerebrovasdis.2004.03.003.
8
Carotid artery stenosis in ischemic stroke patients with nonvalvular atrial fibrillation.非瓣膜性心房颤动缺血性卒中患者的颈动脉狭窄
Cerebrovasc Dis. 2002;13(1):16-20. doi: 10.1159/000047740.